[A20-04] Ivacaftor (cystic fibrosis, 6 years and older, with G551D mutation) - Addendum to Commission A19-65
Last updated 20.03.2020
Project no.:
A20-04
Commission:
Commission awarded on 07.01.2020 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
Indication:
Cystic fibrosis (CF) in patients aged 6 years and older and weighing 25 kg or more who have a G551D mutation in the CFTR gene
Result of dossier assessment:
Conclusion of dossier assessment A19-65 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-65 | Ivacaftor (cystic fibrosis, 6 years and older, with G551D mutation) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.